Tag Archives: uthr

United Therapeutics Legal Victory Sends Stock Flying

United Therapeutics (UTHR) scored a legal victory over Sandoz in a 2-year-old patent case that will likely provide additional legal protection for United’s Remodulin drug, which treats breathing problems for people with arterial hypertension. United Therapeutics stock soared to an all-time of 118 on the victory. In midday trading in the stock market today, United Therapeutics was up nearly 26%, near 115.50. In an email to client Friday, ISI Group

United Therapeutics Q4 Revenue Misses, Stock Slides

Biotech United Therapeutics (UTHR) missed Q4 sales estimates and reported higher-than-expected expenses Tuesday, sending shares down 1% in midday trading on the stock market today. The company said sales totaled $289 million, up 19% from the year-earlier quarter but missing analysts’ consensus by $6 million. The shortfall came in its lead drug, Remodulin, a treatment for pulmonary arterial hypertension. Its sales were about $7 million short of

United Therapeutics Hits High After FDA Approval

United Therapeutics (UTHR) stock jumped to an all-time Monday in reaction to the company’s announcement late Friday of federal approval for its drug to treat hypertension. United Therapeutics stock was up more than 22% in morning trading in the stock market today, near 107.50. The stock has more than doubled in 2013 and has an IBD Relative Strength Rating of 85. Late Friday, the company said the Food and Drug Administration had approved its